Over at Genetic Future, Daniel MacArthur blogs about Complete Genomics and its deal to sequence five genomes for the Broad Institute -- one genome of a well-studied test case, and four from "tumor and matched-pair normals" to study glioblastoma and melanoma. MacArthur spoke with Complete's Geoff Nilsen about accuracy issues.
To read the full story....
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.